We are live on ! Find out more
NVS icon

Novartis

909 hedge funds and large institutions have $19.9B invested in Novartis in 2017 Q1 according to their latest regulatory filings, with 76 funds opening new positions, 342 increasing their positions, 335 reducing their positions, and 61 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more first-time investments, than exits

New positions opened: 76 | Existing positions closed: 61

9% more capital invested

Capital invested by funds: $18.3B → $19.9B (+$1.61B)

2% more repeat investments, than reductions

Existing positions increased: 342 | Existing positions reduced: 335

0.71% more ownership

Funds ownership: 10.65%11.36% (+0.71%)

1% more funds holding

Funds holding: 904909 (+5)

5% less funds holding in top 10

Funds holding in top 10: 2120 (-1)

55% less call options, than puts

Call options by funds: $30.9M | Put options by funds: $68.2M

Holders
909
Holders Change
+5
Holders Change %
+0.55%
% of All Funds
22.63%
Holding in Top 10
20
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-4.76%
% of All Funds
0.5%
New
76
Increased
342
Reduced
335
Closed
61
Calls
$30.9M
Puts
$68.2M
Net Calls
-$37.3M
Net Calls Change
-$54.7M
Name Holding Trade Value Shares
Change
Change in
Stake
IHL
226
Investment House LLC
California
$4.72M -$46.5K -698 -1%
LAM
227
Lebenthal Asset Management
New York
$4.68M +$254K +3,813 +6%
CHCM
228
Columbus Hill Capital Management
New Jersey
$4.64M +$4.65M +69,750 New
RW
229
Rand Wealth
Maryland
$4.62M -$197K -2,950 -4%
NCM
230
Nelson Capital Management
California
$4.59M +$55.4K +831 +1%
CIBC World Market
231
CIBC World Market
Ontario, Canada
$4.52M -$2.53M -38,033 -36%
WFG
232
Windsor Financial Group
Minnesota
$4.5M -$89.2K -1,339 -2%
CTA
233
Chesley Taft & Associates
Illinois
$4.45M +$20.8K +312 +0.5%
OWD
234
Osborn Williams & Donohoe
Ohio
$4.43M -$134K -2,017 -3%
TRIM
235
Thompson Rubinstein Investment Management
Oregon
$4.36M -$35.7K -536 -0.8%
ARMC
236
American Research & Management Company
Massachusetts
$4.35M -$22.3K -334 -0.5%
Creative Planning
237
Creative Planning
Kansas
$4.32M -$523K -7,850 -11%
EGA
238
Eagle Global Advisors
Texas
$4.3M -$274K -4,115 -6%
ECM
239
ETrade Capital Management
Virginia
$4.22M +$124K +1,867 +3%
CT
240
Cambridge Trust
Massachusetts
$4.09M -$944K -14,171 -19%
AllianceBernstein
241
AllianceBernstein
Tennessee
$4.09M +$1.05M +15,714 +34%
TCM
242
Tradition Capital Management
New Jersey
$4.04M -$189K -2,843 -4%
HA
243
Hamel Associates
New Jersey
$4M +$163K +2,446 +4%
HWM
244
Holloway Wealth Management
Florida
$4M
NFA
245
Nationwide Fund Advisors
Ohio
$3.98M +$299K +4,481 +8%
WI
246
Welch Investments
Alabama
$3.88M +$713K +10,695 +22%
HKIM
247
Hayek Kallen Investment Management
Alabama
$3.84M +$39.8K +597 +1%
CNB
248
Camden National Bank
Maine
$3.77M +$190K +2,845 +5%
BCM
249
Bourgeon Capital Management
Connecticut
$3.75M +$26.1K +391 +0.7%
GCM
250
Garland Capital Management
Washington
$3.75M -$108K -1,618 -3%

NVS Hedge Fund Activity: Q1 2017 in Review

909 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q1 2017, worth a combined $19.9B — up 8.8% from $18.3B a quarter earlier.

Buyers outnumbered sellers: 76 funds opened new NVS positions and 61 closed out — a net gain of 15 holders — while 342 added to existing stakes and 335 trimmed.

The largest buyer was Dodge & Cox, adding an estimated $362M. The largest seller was 1832 Asset Management, cutting an estimated $239M.

  • 909 institutional investors held Novartis (NVS) as of Q1 2017, up from 904 in Q4 2016.
  • Funds reported $19.9B of Novartis stock for Q1 2017, up 8.8% quarter-over-quarter.
  • 76 funds opened new Novartis positions in Q1 2017 and 61 closed out, a net change of +15 holders.
  • The largest Novartis buyer in Q1 2017 was Dodge & Cox, an estimated $362M added.
  • The largest Novartis seller in Q1 2017 was 1832 Asset Management, an estimated $239M sold.

Based on aggregated 13F filings for Q1 2017.